Pathway Impact Factor Calculation for Gene Signaling Networks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pathway analysis techniques fail to account for the topology and interactions within gene signaling networks, leading to false positives and false negatives, and are unable to estimate the impact of expression changes on specific pathways, limiting their effectiveness in understanding disease mechanisms.
Innovation Solution
A novel impact factor calculation method that incorporates normalized fold change, statistical significance, and pathway topology to assess the significance and perturbation of gene signaling pathways, providing a more comprehensive analysis by considering the position and interactions of genes within pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pathway analysis techniques (ORA or FCS) are used to analyze gene signaling networks, then the analysis can be performed using available tools, but the topology and interactions within pathways are ignored, leading to false positives and false negatives
Solution Approach 1:
The patent segments the pathway analysis into two distinct components: (1) statistical significance assessment using ORA or FCS methods to evaluate whether pathway genes are over-represented, and (2) topology-based perturbation analysis using PageRank to evaluate the impact of gene expression changes on pathway function. This segmentation allows each component to address specific aspects independently, improving overall reliability while maintaining manageable complexity through modular implementation.
Solution Approach 2:
The patent merges the statistical significance score with the topology-based perturbation score to create a comprehensive pathway impact assessment. By combining these two previously separate analytical approaches, the method captures both the statistical evidence for pathway involvement and the functional impact of gene perturbations, thereby reducing false positives and false negatives without requiring a completely new complex framework.
2Loss of information
If pathway analysis considers only the set of genes on a pathway, then the analysis is simple to perform, but the position and interactions of genes within pathways are ignored, resulting in biologically meaningless results
Solution Approach 1:
The patent introduces PageRank as an intermediary computational approach that bridges the gap between simple gene set analysis and complex systems biology models. PageRank serves as a mediator that incorporates topology information and gene interaction relationships without requiring the full complexity of dynamic systems modeling, thus recovering lost topology information while maintaining computational tractability.
Solution Approach 2:
The patent changes the analytical parameter from merely counting pathway genes to evaluating the perturbation propagation through the pathway network using PageRank. This parameter transformation allows the method to capture topology information by measuring how gene expression changes propagate through the network, providing biologically meaningful results without excessive complexity.
3Measurement precision
If existing analysis methods are used, then computational resources are conserved, but the methods cannot estimate the impact of expression changes on specific pathways, limiting effectiveness in understanding disease mechanisms
Solution Approach 1:
The patent applies partial action by focusing the topology-based perturbation analysis only on the specific pathway genes of interest rather than performing exhaustive systems-level simulations. This allows the method to estimate pathway impact with sufficient precision for disease mechanism understanding while avoiding the excessive computational power requirements of complete network dynamics modeling.
Data Source
AI summary
Significance of biological pathway in disease state is predicted by (a) providing expression level data for a plurality of biomolecules differentially expressed in a disease state, compared with same biomolecules expressed in a non-diseased state: (b) determining presence probability of the biomolecules in disease state; (c) determining effect of each biomolecule from the plurality of biomolecules on the expression of different downstream biomolecules within pathway to provide perturbation factor for each biomolecule in the pathway; (d) combining statistical significance of differentially expressed biomolecules present in the disease state, with a sum of perturbation factors for all of the biomolecules, generating an impact factor; (e) calculating statistical significance of impact factor based upon determined probability of having statistical significant presence of differentially expressed biomolecules in step (b) and the sum of perturbation factors in step (c); and (f) outputting statistical significance of impact factor for the pathway relevant to the disease.